Merck Strengthens Immunology Pipeline with Acquisition of Prometheus Biosciences, Inc.
PRA023 is a novel, late-stage candidate for ulcerative colitis and Crohn’s disease and other autoimmune conditions Prometheus Biosciences’ comprehensive data...